Johnson & Johnson backs FY18 adj. EPS view $8.13-$8.18, consensus $8.16

Backs FY18 revenue view $81B-$81.4B, consensus $81.34B.
https://thefly.com/landingPageNews.php?id=2838243

Vertex initiated at Guggenheim

Vertex resumed with a Neutral at Guggenheim. Guggenheim analyst Whitney Ijem resumed coverage of Vertex Pharmaceuticals with a Neutral rating. The analyst thinks a successful launch of the triple combo is priced into the shares and that the risk/reward on progress is “skewed to the downside at this stage.” Further, she thinks any competitive cystic fibrosis updates could be an overhang and the “what’s next” question will become more important.
https://thefly.com/landingPageNews.php?id=2838247

Universal Health authorizes $500M increase to share repurchase program

Universal Health Services announced that its Board of Directors authorized a $500M increase to its stock repurchase program. This authorization will increase the aggregate authorization to $1.7B from the previous $1.2B authorization, which was approved in 2014, 2016 and 2017. Since the inception of this program, we have repurchased approximately 10M shares at an aggregate cost of approximately $1.16B.
https://thefly.com/landingPageNews.php?id=2838225

Baxter initiated at Credit Suisse

Baxter initiated with an Outperform at Credit Suisse. Credit initiated Baxter with an Outperform rating and $77 price target.
https://thefly.com/landingPageNews.php?id=2838207

Globus Medical initiated at Credit Suisse

Globus Medical initiated with an Outperform at Credit. Credit Suisse initiated Globus Medical with an Outperform rating and $53 price target.
https://thefly.com/landingPageNews.php?id=2838213

Boston Scientific initiated at Credit Suisse

Boston Scientific initiated with an Outperform at Credit Suisse. Credit Suisse initiated Boston Scientific with an Outperform and $42 price target.
https://thefly.com/landingPageNews.php?id=2838187

Integra LifeSciences initiated at Credit Suisse

Integra LifeSciences initiated with an Outperform at Credit Suisse. Credit Suisse initiated Integra LifeSciences with an Outperform and $57 price target
https://thefly.com/landingPageNews.php?id=2838191